3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Hepatocellular
20
Carcinoma, Renal Cell
15
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Endometrial Neoplasms
7
Neoplasms
4
Biliary Tract Neoplasms
4
Uterine Cervical Neoplasms
3
Neuroendocrine Tumors
3
Liver Neoplasms
3
Vulvar Neoplasms
2
Triple Negative Breast Neoplasms
2
Thyroid Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Colorectal Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Non-Small-Cell Lung
2
von Hippel-Lindau Disease
1
Thyroid Carcinoma, Anaplastic
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Penile Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Lung Neoplasms
1
Kidney Neoplasms
1
Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
1
Interventions
Cyclophosphamide
25
fludarabine
19
Dexamethasone
17
pembrolizumab
13
Rituximab
12
venetoclax
9
Lenalidomide
9
Gemcitabine
9
Etoposide
9
pomalidomide
8
Vincristine
7
glofitamab
6
fludarabine phosphate
6
carfilzomib
6
Temozolomide
6
obinutuzumab
5
daratumumab
5
Prednisone
5
Nivolumab
5
Doxorubicin
5
Cisplatin
5
Calcium Dobesilate
5
Bortezomib
5
zanubrutinib
4
selinexor
4
Immunotherapy, Adoptive
4
Cytarabine
4
Carboplatin
4
Azacitidine
4
ruxolitinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Recurrence
×
lenvatinib
×
90 days
×
Clear all
No trials found.